Lung Cancer Considered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Mark Lewis and Dr. Michael Maddaus for a candid conversation about physician wellness, burnout, grief, and resilience. Drawing from their personal and professional experiences, they explore the hidden emotional toll of caring for patients with cancer, the limitations of the “just be more resilient” mindset, and the importance of self-compassion, vulnerability, and seeking support.

Dr. Mark Lewis is Director of Gastrointestinal Oncology at Intermountain Health. He has become a leading voice on physician well-being, patient-centered care, and the emotional realities of oncology practice.

Dr. Michael Maddaus is a cardiovascular and thoracic surgeon at the University of Minnesota.

As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The discussion reviews advances in ALK+ non-small cell lung cancer (NSCLC).

Thymic epithelial tumors are rare but complex thoracic cancers that require specialized diagnosis and multidisciplinary management. In this episode of Lung Cancer Considered, Dr. Stephen Liu is joined by Dr. Nicolas Girard and Dr. Erica Pietroluongo to discuss the diagnosis, staging, and treatment of thymoma and thymic carcinoma, including current standards of care, evolving systemic therapies, and promising areas of research. They also highlight the importance of international collaboration in advancing care for patients with these rare malignancies.

Guests:

Nicolas Girard, MD, PhD
Head of the Thorax Institute Curie Montsouris,
Institut Curie, Paris, France

Erica Pietroluongo, MD, PhD
Medical Oncologist, University Federico II, Naples
Visiting Scholar, University of Chicago

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer.

Guests:

Alexander Drilon, MD
Chief, Early Drug Development Service
Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College

Rosario Charo Garcia Campelo, MD
Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital
Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology.
Key Topics Covered:
• ALK-positive lung cancer
• Cellular Therapy
• Vaccines

Guests:

Vincent Lam, MD
Associate Professor of Oncology, Johns Hopkins University School of Medicine
Director, Thoracic Oncology Clinical Research Program
Sidney Kimmel Comprehensive Cancer Center

Carmen Mecca. PhD
Postdoctoral Fellow, Chiarle Lab
Department of Pathology
Boston Children’s Hospital